Patents by Inventor Pasi A. Janne

Pasi A. Janne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER
    Publication number: 20190145977
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: January 23, 2019
    Publication date: May 16, 2019
    Inventors: Kwok-Kin WONG, Bruce E. JOHNSON, Pasi A. JANNE, Hongbin JI, Nabeel BARDEESY, Norman E. SHARPLESS, Diego H. Castrillon
  • Pyrimidines as EGFR inhibitors and methods of treating disorders
    Patent number: 10266517
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 23, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Pasi Janne, Hwan Geun Choi, Jaebong Jang
  • BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE
    Publication number: 20190106417
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 11, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jaebong Jang, Dries De Clercq, Michael Eck, Pasi Janne
  • EGFR Inhibitors and Methods of Treating Disorders
    Publication number: 20190040065
    Abstract: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Application
    Filed: March 2, 2018
    Publication date: February 7, 2019
    Inventors: Nathanael S. Gray, Pasi Janne, Michael J. Eck, Wenjun Zhou
  • BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE
    Publication number: 20190016703
    Abstract: The present invention provides bifunctional compounds which act as protein degradation inducing moieties for a HER family protein, such as Her3. The present invention also provides methods for the targeted degradation of a HER family protein through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to the HER family protein which can be utilized in the treatment of disorders modulated by a HER family protein.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 17, 2019
    Inventors: Nathanael S. GRAY, James BRADNER, Pasi JANNE, Jaebong JANG, Hwan Geun CHOI, Eunhwa KO, Joong-Heui CHO
  • HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION
    Publication number: 20180354954
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 13, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., Yale University
    Inventors: Nathanael S. Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews
  • INHIBITORS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20180290975
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: June 30, 2016
    Publication date: October 11, 2018
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • INHIBITORS OF ALK AND SRPK AND METHODS OF USE
    Publication number: 20180258040
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 13, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: John HATCHER, Nathanael S. GRAY, Hwan Geun CHOI, Pasi JANNE, Tinghu ZHANG
  • NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20180194758
    Abstract: The application relates to a compound having Formula (I?): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: July 20, 2016
    Publication date: July 12, 2018
    Inventors: Nathanael S. GRAY, Jaebong JANG, Pasi JANNE
  • HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION
    Publication number: 20180093990
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Application
    Filed: September 8, 2017
    Publication date: April 5, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., Yale University
    Inventors: Nathanael S. Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews
  • EGFR inhibitors and methods of treating disorders
    Patent number: 9908884
    Abstract: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 6, 2018
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Pasi Janne, Michael J. Eck, Wenjun Zhou
  • NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20170362204
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 21, 2017
    Inventors: Nathanael S. GRAY, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG
  • Hydrophobically tagged small molecules as inducers of protein degradation
    Patent number: 9758522
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 12, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Yale University
    Inventors: Nathanael Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews
  • METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS
    Publication number: 20170073760
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Application
    Filed: December 11, 2015
    Publication date: March 16, 2017
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • NON-INVASIVE BLOOD BASED MONITORING OF GENOMIC ALTERATIONS IN CANCER
    Publication number: 20160138112
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 19, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION
    Publication number: 20150274738
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Application
    Filed: October 18, 2013
    Publication date: October 1, 2015
    Applicants: Dana-Farber Cancer, Institute, Inc., Yale University
    Inventors: Nathanael Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews
  • METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS
    Publication number: 20140296100
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 2, 2014
    Applicants: Dana Farber Cancer Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Methods for treating cancer resistant to ErbB therapeutics
    Patent number: 8715665
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: May 6, 2014
    Assignees: The General Hospital Corporation, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS
    Publication number: 20120225870
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Application
    Filed: April 11, 2008
    Publication date: September 6, 2012
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20120094999
    Abstract: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Application
    Filed: May 5, 2010
    Publication date: April 19, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Pasi Janne, Michael J. Eck, Wenjun Zhou